OXE-103 is under clinical development by Oxeia Biopharmaceuticals and currently in Phase II for Traumatic Brain Injury. According to GlobalData, Phase II drugs for Traumatic Brain Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OXE-103 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OXE-103 overview
OXE-103 (SUN11031) is under development for the treatment of traumatic brain injury (which leads to neurodegenerative conditions and concussion) and covid longhauler syndrome (“Long Covid”). The drug candidate is a ghrelin analogue which binds to growth hormone secretagogue receptor GHS-R1a (GHSR) and is administered through subcutaneous injection and through intravenous route. It was also under development for the treatment of cachexia associated with chronic obstructive pulmonary disease and in subjects with anorexia nervosa.
Oxeia Biopharmaceuticals overview
Oxeia Biopharmaceuticals (Oxeia) is a clinical stage biotechnology company that develops drug treatments for mild traumatic brain injury or concussion and underlying neuro-metabolic dysfunction. The company’s lead pipeline candidate includes OXE-103, potent mitochondrial stabilizer that crosses the blood brain barrier and activates a well-characterized pathway that promotes normal mitochondrial activity. It also provides medical solutions to aid recovery. The company conducts human clinical research for drug development. It partners with pharmaceutical and biotechnology companies. Oxeia is headquartered in San Diego, California, the US.
For a complete picture of OXE-103’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
